Source comparison
Melanotan-2 Dosing Protocols: Research Use Comparison
Conservative Titration 0.25mg daily 10–14 days 0.5mg per dose 2× weekly 1mg/week Minimal nausea, mild flushing in <20% of subjects Best for Fitzpatrick Type I–II subjects or those prioritising tolerability over speed Standard Protocol 0.5mg daily 7–10 days 0.7
This comparison does not assign a generated winner or score.
- Conservative Titration
- 0.25mg daily
- 10–14 days
- 0.5mg per dose
- 2× weekly
- 1mg/week
- Minimal nausea, mild flushing in <20% of subjects
- Best for Fitzpatrick Type I–II subjects or those prioritising tolerability over speed
- Standard Protocol
- 0.5mg daily
- 7–10 days
- 0.75mg per dose
- 2–3× weekly
- 1.5–2.25mg/week
- Moderate nausea during loading (30–40% incidence), resolves by day 5–7
- Gold standard for most research applications. Balances efficacy and tolerability
- Aggressive Loading
- 0.5mg daily (days 1–3), 1mg daily (days 4–10)
- 10 days
- 1mg per dose
- 3× weekly
- 3mg/week
- High nausea incidence (50–60%), spontaneous erections, facial flushing lasting 2–4 hours
- Only appropriate for subjects with prior melanocortin agonist exposure or Type IV+ baseline pigmentation
- Maintenance-Only (No Loading)
- N/A
- Delayed pigmentation onset (3–4 weeks vs 10–14 days), inconsistent results
- Not recommended. Cumulative dose without loading phase rarely achieves target melanogenesis within standard research timelines